Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?

BACKGROUND: When a new drug comes to the market, the incentive for the sponsoring company is to maximize the treatment duration in order for the patient to reap the full therapeutic benefit of the product and achieve a positive trial result. We sought to enumerate instances when an already-approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Haslam, A., Olivier, T., Thawani, R., Prasad, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271471/
https://www.ncbi.nlm.nih.gov/pubmed/35468562
http://dx.doi.org/10.1016/j.esmoop.2022.100480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271471/
https://www.ncbi.nlm.nih.gov/pubmed/35468562
http://dx.doi.org/10.1016/j.esmoop.2022.100480

Ejemplares similares